10 June 2022 - Breakthrough therapy designations granted for ROS1 positive non-small-cell lung cancer patients pretreated with one prior line of ROS1 tyrosine kinase inhibitor with or without prior chemotherapy.

Zai Lab today announced that the Center for Drug Evaluation of the National Medical Products Administration granted two breakthrough therapy designations for investigational repotrectinib for the treatment of patients with ROS1 positive metastatic non-small-cell lung cancer who have received one prior line of ROS1 tyrosine kinase inhibitor and one prior line of platinum-based chemotherapy and for those with ROS positive metastatic non-small-cell lung cancer who have received one prior line of ROS1 tyrosine kinase inhibitor and no chemotherapy or immunotherapy.

Read Zai Labs press release